Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 29;57(8):770.
doi: 10.3390/medicina57080770.

Presepsin as Early Marker of Sepsis in Emergency Department: A Narrative Review

Affiliations
Review

Presepsin as Early Marker of Sepsis in Emergency Department: A Narrative Review

Andrea Piccioni et al. Medicina (Kaunas). .

Abstract

The diagnosis and treatment of sepsis have always been a challenge for the physician, especially in critical care setting such as emergency department (ED), and currently sepsis remains one of the major causes of mortality. Although the traditional definition of sepsis based on systemic inflammatory response syndrome (SIRS) criteria changed in 2016, replaced by the new criteria of SEPSIS-3 based on organ failure evaluation, early identification and consequent early appropriated therapy remain the primary goal of sepsis treatment. Unfortunately, currently there is a lack of a foolproof system for making early sepsis diagnosis because conventional diagnostic tools like cultures take a long time and are often burdened with false negatives, while molecular techniques require specific equipment and have high costs. In this context, biomarkers, such as C-Reactive Protein (CRP) and Procalcitonin (PCT), are very useful tools to distinguish between normal and pathological conditions, graduate the disease severity, guide treatment, monitor therapeutic responses and predict prognosis. Among the new emerging biomarkers of sepsis, Presepsin (P-SEP) appears to be the most promising. Several studies have shown that P-SEP plasma levels increase during bacterial sepsis and decline in response to appropriate therapy, with sensitivity and specificity values comparable to those of PCT. In neonatal sepsis, P-SEP compared to PCT has been shown to be more effective in diagnosing and guiding therapy. Since in sepsis the P-SEP plasma levels increase before those of PCT and since the current methods available allow measurement of P-SEP plasma levels within 17 min, P-SEP appears a sepsis biomarker particularly suited to the emergency department and critical care.

Keywords: ICU; Presepsin; critical care; emergency department; sepsis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
P-SEP is the 13 KDa N-terminal fragment of soluble form of CD14 (sCD14), cleaved by cathepsin D in plasma, and involved in activating the innate immune system.

References

    1. Ulla M., Pizzolato E., Lucchiari M., Loiacono M., Soardo F., Forno D., Morello F., Lupia E., Moiraghi C., Mengozzi G., et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: A multicenter prospective study. Crit. Care. 2013;17:R168. doi: 10.1186/cc12847. - DOI - PMC - PubMed
    1. Balci C., Sungurtekin H., Gürses E., Sungurtekin U., Kaptanoğlu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit. Care. 2002;7:85–90. doi: 10.1186/cc1843. - DOI - PMC - PubMed
    1. Harbarth S., Holeckova K., Froidevaux C., Pittet D., Ricou B., Grau G.E., Vadas L., Pugin J., Network G.S. Diagnostic value of procalcitonin, interleukin-6, and in- terleukin-8 in critically ill patients admitted with suspected sepsis. Am. J. Respir. Crit. Care Med. 2001;164:396–402. doi: 10.1164/ajrccm.164.3.2009052. - DOI - PubMed
    1. Yusa T., Tateda K., Ohara A., Miyazaki S. New possible biomarkers for diagnosis of infections and diagnostic distinction between bacterial and viral infections in children. J. Infect. Chemother. 2017;23:96–100. doi: 10.1016/j.jiac.2016.11.002. - DOI - PubMed
    1. Alizadeh N., Memar M.Y., Moaddab S.R., Kafil H.S. Aptamer-assisted novel technologies for detecting bacterial pathogens. Biomed. Pharmacother. 2017;93:737–745. doi: 10.1016/j.biopha.2017.07.011. - DOI - PubMed